Adolor Corporation (NASDAQ:ADLR) announced today that over 500 hospitals have now enrolled in the Entereg Access Support & Education (E.A.S.E.(TM)) Program. The Company estimates that these hospitals perform approximately 20% of the annual bowel resection procedures in the United States. The E.A.S.E.

Entereg(R) (alvimopan) capsules is now available to registered hospitals for helping patients recover gastrointestinal (GI) function earlier following bowel resection surgery. Entereg was approved by the U.S.

Adolor Corporation (Nasdaq:ADLR) and GlaxoSmithKline (NYSE:GSK) announced today that the U.S. Food and Drug Administration has approved Entereg(R) (alvimopan) capsules to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

Adolor and GlaxoSmithKline have reported that the FDA has extended the Prescription Drug User Fee Act action date for the new drug application of Entereg (alvimopan) to May 10, 2008. The NDA for Entereg 12mg capsules is for in-hospital, short-term use for the management of postoperative ileus (POI).

Adolor Corporation (Nasdaq:ADLR) and GlaxoSmithKline (NYSE:GSK) today announced that a majority (9-6) of the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S.